© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#elafibranor

Lanifibranor Both Resolves NASH and Reduces Liver Fibrosis

The experimental therapy improved liver inflammation, fibrosis and metabolic parameters in six months.

What’s in the Pipeline for NAFLD and NASH Treatment?

Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.

Company Halts Leading NASH Drug but Another Shows Promise

Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.

When Will We See Drug Treatments for NASH Fibrosis?

Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.

International Liver Congress Roundup

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

Elafibranor Shows Favorable Efficacy & Safety as PBC Treatment

Among those with primary biliary cholangitis, the investigational drug reduced alkaline phosphatase levels.
Generic image

NAFLD/NASH Medications

The NAFLD/NASH medications’ page includes specific information about each of the experimental dru...
Advertisement

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.